Drug Trial Radar · NCT07890454
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Dec 28, 2027
Study completion Dec 28, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01
Conditions
- Immunization
- Healthy Volunteers
- COVID-19 Immunization
- Influenza Immunization
Interventions
IIV-HD (standalone)Drug
Pharmaceutical form: Suspension Route of administration: Intramuscular injection
NVXC19 (EU licensed, standalone)Drug
Pharmaceutical form: Dispersion Route of administration: Intramuscular injection
IIV-HD + NVXC19 combinationDrug
Pharmaceutical form: Suspension Route of administration: Intramuscular injection
Placebo, normal salineDrug
Pharmaceutical form: Solution Route of administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antibody titers against for each of the 3 influenza vaccine strains(in a subset of participants)Time frame: At Day 28 after vaccination
- Antibody titers against SARS-CoV-2 specific variant(in a subset of participants)Time frame: At Day 28 after vaccination
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 6160002
Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting
Investigational Site Number : 6160020
Gdynia, Pomeranian Voivodeship, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.